You searched for methotrexate - MPR
Skip to navigation Skip to main content

Your search for methotrexate returned 400 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Your search for methotrexate returned 400 results

Sort Results:

Relevant Recent
Drug Monograph

Methotrexate Injection

Methotrexate 25mg/mL; soln for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free.

Select the therapeutic use below to view the corresponding drug monograph

Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.

Drug Monograph

Methotrexate for Injection

Methotrexate 1g/vial; pwd for IV, IM, intra-arterial, or intrathecal administration after dilution; preservative-free.

Select the therapeutic use below to view the corresponding drug monograph

Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.

Drug Monograph

RASUVO

Methotrexate (MTX) 7.5mg/0.15mL, 10mg/0.20mL, 12.5mg/0.25mL, 15mg/0.30mL, 17.5mg/0.35mL, 20mg/0.40mL, 22.5mg/0.45mL, 25mg/0.50mL, 30mg/0.60mL; soln for SC inj; preservative-free.

Select the therapeutic use below to view the corresponding drug monograph

Visit the related Resource Center for drug monographs, news, CME and other clinical tools for this drugs’ particular therapeutic area.

Trial Tracker

Combo Tofacitinib Plus Methotrexate vs Adalimumab Plus Methorexate Tx

Publish Date
Fleischmann, R et al. "Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial." DOI: http://dx.doi.org/10.1016/S0140-6736(17)31618-5
ACR/ARHP Annual Meeting 2015

Subcutaneous Methotrexate Underutilized for RA, Study Finds

Publish Date
Methotrexate is frequently under-dosed, administered for an inadequate duration, and rarely switched to subcutaneous injection prior to initiating biologic therapy, James R. O'Dell, MD, from the University of Nebraska Medical Center, Omaha, NE, reported at the 2015 ACR/ARHP Annual Meeting.